These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 19192611

  • 1. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P.
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, Ciaffi L, Brulet C, Peytavin G, Vergne L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    AIDS; 2007 Mar 30; 21(6):768-71. PubMed ID: 17413701
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 30; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, Kashuba AD.
    AIDS; 2007 Jan 02; 21(1):59-64. PubMed ID: 17148968
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul 02; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.
    J Med Assoc Thai; 2006 Sep 02; 89(9):1472-8. PubMed ID: 17100387
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE.
    Trop Med Int Health; 2005 May 02; 10(5):464-70. PubMed ID: 15860093
    [Abstract] [Full Text] [Related]

  • 12. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
    Pensi T.
    Indian Pediatr; 2007 Jul 02; 44(7):519-21. PubMed ID: 17684304
    [Abstract] [Full Text] [Related]

  • 13. [Primary results of antiretroviral treatment among HIV/AIDS infected children in Lomé (Togo)].
    Atakouma DY, Tsolenyanu E, Gbadoe A, Gbetoglo V, Lawson-Evi K, Agbere AR, Tatagan-Agbi K, Assimadi K.
    Arch Pediatr; 2007 Oct 02; 14(10):1178-82. PubMed ID: 17531452
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 02; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 17. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Nov 13; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 18. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO.
    Niger J Clin Pract; 2008 Dec 13; 11(4):312-5. PubMed ID: 19320401
    [Abstract] [Full Text] [Related]

  • 19. [A fixed dose anti-HIV combination for the poor? Triomune].
    Garcia MV, Mukeba-Tshialala D, Vaira D, Moutschen M.
    Rev Med Liege; 2009 Jan 13; 64(1):32-6. PubMed ID: 19317099
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.